PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada (PARTHENON)

Novartis

Status: Completed

Conditions: Heart Failure

Treatments: Drug: sacubitril/valsartan

Study type: Observational

Funder types: Industry

Identifiers

NCT02957409

CLCZ696BCA03

Details and patient eligibility

About

The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.

Full description

The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.

Enrollment: 1,009 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Receiving sacubitril/valsartan as per the Canadian product label and treatment initiation within the last 3 months
• Able to communicate with investigator

Exclusion criteria

• Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days
• Presence of any condition that in the opinion of the investigator, prohibits patient from participating in the trial

Trial design

1,009 participants in 1 patient group

sacubitril/valsartan

Description:

Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period

Treatment:

Drug: sacubitril/valsartan